Video

J. Bergh comments on 3 studies on the use of bevacizumab in breast cancer: as adjuvant treatment in HER2 negative disease (E5103); as maintenance therapy in the metastatic setting (Arobase); as neoadjuvant treatment (Avataxher) in early HER2 positive breast cancer.